??????????????????????????????????????????????????????

Abstract

There are strong evidences to support the idea that follicle-stimulating hormone (FSH) plays an important role in regulation of bone mass. Owing to its limited expression to gonadal tissues and osteoclasts and its precursor monocytes, FSH receptor may be a good target for FSH blocking therapy. High titers of polyclonal rabbit anti-human FSHR antibody (pAbFSHR) was raised and prepared. The bilateral ovariectomized (OVX) Sprague-Dawley (SD) rats were used as the osteoporosis model for evaluating the effects of pAbFSHR and FSH inhibitor leuprorelin(LE) on the bone loss. The results showed after treatment with pAbFSHR and LE separately, the FSH and luteinizing hormone(LH) levels in OVX groups decreased significantly (P<0.05) compared with PBS treated OVX rats. No significant differences of estrogen (E2) levels were detected between treatment and PBS injected OVX rats (P>0.05). In addition, the number of trabecular bone increased after pAbFSHR treatment in OVX groups in the shin bone histologic analysis. The results suggested targeting against FSHR may work on the treatment of osteoporosis.

PDF???